A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. Check foractive clinical trials using this agent. OR A drug that is used to treat myelodysplastic syndromes and is being studied in the treatment of other types of cancer. It is a type of antimetabolite. Also called decitabine.